Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

329
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
329
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis.

Clinical pharmacokinetics·2026
Same author

Implications of the EHA/ELN guidelines for reporting blast percentage. Comment on: "Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel".

Haematologica·2026
Same author

Error processing in major depressive disorder: a systematic review and meta-analysis of event-related potential studies.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026
Same author

Platform Assessment of Concentration-QTc Relationship Across GalNAc-siRNA Molecules.

Clinical pharmacokinetics·2025
Same author

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: Apr 3, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

FDA Approval: Blinatumomab.

Donna Przepiorka1, Chia-Wen Ko2, Albert Deisseroth2

  • 1Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland. donna.przepiorka@fda.hhs.gov.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 17, 2015
PubMed
Summary
This summary is machine-generated.

Blinatumomab offers a new treatment for relapsed or refractory B-cell acute lymphoblastic leukemia, achieving complete remission in 32% of patients. Further randomized trials are needed to confirm its clinical benefit.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.6K

Related Experiment Videos

Last Updated: Apr 3, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.6K

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Philadelphia chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R/R ALL) presents a significant treatment challenge.
  • Blinatumomab represents a novel therapeutic approach targeting CD19-expressing leukemia cells.

Purpose of the Study:

  • To evaluate the efficacy and safety of blinatumomab in adults with R/R ALL.
  • To provide data supporting the accelerated approval of blinatumomab.

Main Methods:

  • A single-arm clinical trial involving 185 evaluable adult patients with R/R ALL.
  • Assessment of complete remission (CR) rates, duration of response, and minimal residual disease (MRD) response.
  • Monitoring of adverse events and laboratory abnormalities.

Main Results:

  • A CR rate of 32% (95% CI, 26%-40%) was observed.
  • The median duration of response was 6.7 months.
  • MRD response was achieved by 31% of patients (95% CI, 25%-39%).

Conclusions:

  • Blinatumomab demonstrated significant efficacy in R/R ALL, supporting its accelerated FDA approval.
  • Serious toxicities included cytokine release syndrome and neurologic events.
  • A confirmatory randomized trial is necessary to establish definitive clinical benefit.